Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., This strategic move allows Apollomics’ A shares and warrants to be traded on the NASDAQ under the ticker symbols “APLM” and “APLMW” respectively. The merger, which was approved by Maxpro’s shareholders on March 20, 2023, is projected to inject USD 23.65 million into Apollomics, funds that are designated for research and development efforts. Dr. Yu Guoliang will continue in his role as CEO and director of the board for Apollomics.
Apollomics’ Global Presence and Support
Officially headquartered in Foster City, California, Apollomics Inc. maintains a robust presence in China with operations in Shanghai and Hangzhou. The company enjoys the support of a diverse group of Chinese investors, including Ping An Capital, China Renaissance, and CMB International, among others. Apollomics is actively developing a pipeline of nine assets, which encompasses both small-molecule drugs and biologics.
Pipeline Highlights and Clinical Progress
The company’s pipeline is spearheaded by vebreltinib, a c-Met inhibitor that is in pivotal Phase II studies for non-small cell lung cancer (NSCLC), with expectations to support a future US New Drug Application (NDA) filing. Additionally, uproleselan, an E-selectin antagonist, is in Phase III trials in China for the treatment of relapsed or refractory acute myeloid leukemia (AML). This molecule has previously been granted breakthrough therapy designations (BTDs) in both the US and China, highlighting its potential impact on patient care.-Fineline Info & Tech
